Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...
Impact of geographic and demographic characteristics on treatment with Lu-PSMA for metastatic castrate-resistant prostate cancer (mCRPC). Rucaparib vs docetaxel (DTX) or second-generation androgen ...
Please provide your email address to receive an email when new articles are posted on . Men with metastatic castration-resistant prostate cancer had significantly longer OS with docetaxel rechallenge ...
Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
Oncology Media Relations oncology_media_relations@its.jnj.com Investor contact: Jessica Margevich investor-relations@its.jnj.com ...
Erleada significantly reduces the risk of death by 51% in mCSPC patients compared to Nubeqa, without chemotherapy, over 24 months. The study used inverse probability of treatment weighting to ensure ...
Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results